LINDSEY RUX: Open Payments
NPI 1477105856 · PRICE, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$730 in 36 payments from 15 companies in 2025. Trend: 2023 $285 · 2024 $480 · 2025 $730
Food & beverage: $730
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 12 | $258 |
| AstraZeneca Pharmaceuticals LP | 5 | $103 |
| Supernus Pharmaceuticals, Inc. | 3 | $62 |
| Novo Nordisk Inc | 2 | $41 |
| HARMONY BIOSCIENCES LLC | 2 | $37 |
| Neurocrine BioSciences, Inc. | 2 | $37 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $36 |
| SANOFI-AVENTIS U.S. LLC | 1 | $26 |
| Organon LLC | 1 | $25 |
| Axsome Therapeutics, Inc. | 1 | $25 |
Products named: VRAYLAR, AIRSUPRA, UBRELVY, QULIPTA, Qelbree, WAKIX, INGREZZA, Kerendia.
Industry payments across UT — which companies pay providers there.
